HUM vs LLY
Humana · Eli Lilly
| HUM Humana Healthcare | LLY Eli Lilly Healthcare | |
|---|---|---|
| Market | ||
| Price | $414.50 -0.73% | $1,417.54 +3.19% |
| Market cap | $49.8B | $1.33T |
| P/E (TTM) | 38.9 | 48.4 |
| Dividend yield | 0.68% | 0.75% |
| 52-week range | $163.11 – $456.50 | $809.63 – $1,408.38 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Humana’s 22% Medicare Advantage Membership Growth Is Being Dismissed As A Liability — The… Jul 10, 2026 | Eli Lilly (LLY): Two Drugs Drove 88% Of Growth, EPS Hit By $4.57 R&D Oct 31, 2026 |
| Latest earnings | ||
| Reported | — | Oct 29, 2026 |
| Revenue | — | $24.4 billion +39% YoY |
| EPS | — | $7.22 +7% YoY |
| Guidance | — | Guidance raised |
| Revenue growth, last 4 reports | — | +39% +48% |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Shared topics: Guidance
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.